Smartfish joined the Oslo Cancer Cluster in 2014 and currently have two products on the market that have been clinically developed for the use of cancer patients; Nutrifriend 1100 and Nutrifriend 600. Their patented technology is basis for the product range of orally applied liquid emulsions ecpecially suitable for cancer patients.
Looking for collaborators
“Our core expertise as a company is to develop immune-modulating medical nutrition. Currently we have collaborations with both UCLA in the US and Karolinska in Sweden on a new type of medical nutrition we are developing containing curcumine. Recent findings suggests an effect on the natural killer cells (NK-cells) of the immunesystem, which are important in combating cancer,” says Janne Sande Mathisen, Co-Founder and R&D, Smartfish.
Smartfish is now looking for Norwegian collaborators within immuno-oncology/immunetherapy. Interested parties may contact Sande Mathisen directly:
E-mail: email@example.com or Mobile: + 47 93 20 87 02.